Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:leucine derivative
go back to main search page
Accession:CHEBI:47003 term browser browse the term
Definition:An amino acid derivative resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of leucine by a heteroatom. The definition normally excludes peptides containing leucine residues.


show annotations for term's descendants           Sort by:
aloxistatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Capn1 calpain 1 multiple interactions ISO aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] CTD PMID:30910806 NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177 		JBrowse link
G Capn7 calpain 7 multiple interactions ISO aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] CTD PMID:30910806 NCBI chr16:6,545,630...6,581,908
Ensembl chr16:6,545,731...6,581,905 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO
EXP		 [aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein]
[Swainsonine co-treated with aloxistatin] results in increased cleavage of CASP3 protein		 CTD PMID:26853465 PMID:33186601 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of CASP9 protein] CTD PMID:34523043 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ctsb cathepsin B multiple interactions ISO [aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] CTD PMID:30910806 PMID:32186374 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500 		JBrowse link
G Ctsd cathepsin D multiple interactions ISO [aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein CTD PMID:32186374 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488 		JBrowse link
G Ctsl cathepsin L multiple interactions ISO aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] CTD PMID:30910806 NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548 		JBrowse link
G Ddx3x DEAD-box helicase 3, X-linked multiple interactions ISO aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein] CTD PMID:30821613 NCBI chr  X:9,479,532...9,493,169
Ensembl chr  X:9,479,532...9,493,168 		JBrowse link
G Eif4a1 eukaryotic translation initiation factor 4A1 multiple interactions ISO aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein] CTD PMID:30821613 NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858 		JBrowse link
G Eif4h eukaryotic translation initiation factor 4H multiple interactions ISO aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein] CTD PMID:30821613 NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of GAPDH protein] CTD PMID:34523043 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 multiple interactions ISO [aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein CTD PMID:32186374 NCBI chr  X:117,173,097...117,222,090
Ensembl chr  X:117,057,606...117,260,522 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
increases lipidation		 ISO [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; aloxistatin promotes the reaction [indatraline results in increased lipidation of MAP1LC3B protein]
aloxistatin results in increased lipidation of MAP1LC3B protein
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein		 CTD PMID:26483381 PMID:27635674 PMID:32397857 PMID:33124469 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
increases expression		 ISO [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; aloxistatin promotes the reaction [indatraline results in increased expression of SQSTM1 protein]; aloxistatin promotes the reaction [Sertraline results in increased expression of SQSTM1 protein]
aloxistatin results in increased expression of SQSTM1 protein
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein		 CTD PMID:26483381 PMID:32186374 PMID:32773031 PMID:33124469 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
Lipstatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp8 caspase 8 multiple interactions ISO lipstatin analog results in increased cleavage of and results in increased activity of CASP8 protein CTD PMID:20577697 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Eif2a eukaryotic translation initiation factor 2A increases phosphorylation ISO lipstatin analog results in increased phosphorylation of EIF2A protein CTD PMID:20577697 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068 		JBrowse link
G Fasn fatty acid synthase affects binding ISO lipstatin analog binds to FASN protein CTD PMID:20577697 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
methyl L-leucinate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Tnf tumor necrosis factor multiple interactions EXP leucine methyl ester inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] CTD PMID:21748807 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
orlistat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abhd12 abhydrolase domain containing 12, lysophospholipase decreases activity ISO orlistat results in decreased activity of ABHD12 protein CTD PMID:18657971 NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564 		JBrowse link
G Abhd16a abhydrolase domain containing 16A, phospholipase decreases activity ISO orlistat results in decreased activity of ABHD16A protein CTD PMID:18657971 NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927 		JBrowse link
G Acaca acetyl-CoA carboxylase alpha multiple interactions
decreases expression		 ISO Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]
Orlistat results in decreased expression of ACACA mRNA		 CTD PMID:32347045 PMID:33476690 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457 		JBrowse link
G Ache acetylcholinesterase decreases activity ISO Orlistat results in decreased activity of ACHE protein CTD PMID:33844597 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651 		JBrowse link
G Acot8 acyl-CoA thioesterase 8 decreases expression ISO Orlistat results in decreased expression of ACOT8 protein CTD PMID:30667213 NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851 		JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions EXP
ISO		 orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein]
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]		 CTD PMID:25087745 PMID:33476690 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] CTD PMID:32045588 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G App amyloid beta precursor protein multiple interactions ISO [1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid] CTD PMID:28721267 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561 		JBrowse link
G Atf4 activating transcription factor 4 increases expression ISO orlistat results in increased expression of ATF4 mRNA CTD PMID:17283163 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in increased expression of BAX mRNA] CTD PMID:32450208 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in decreased expression of BCL2 mRNA] CTD PMID:32450208 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
multiple interactions		 ISO
EXP		 orlistat results in increased activity of CASP3 protein
orlistat results in increased cleavage of CASP3 protein
Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA]		 CTD PMID:17283163 PMID:20805790 PMID:21723078 PMID:32450208 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO
EXP		 orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein
Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA]		 CTD PMID:18796435 PMID:20577697 PMID:32450208 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions		 ISO
EXP		 orlistat results in increased activity of CASP9 protein
Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP9 mRNA]		 CTD PMID:20805790 PMID:32450208 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase multiple interactions
decreases expression		 EXP
ISO		 Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein]
Orlistat results in decreased expression of CAT protein		 CTD PMID:25087745 PMID:30667213 PMID:32450208 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cck cholecystokinin multiple interactions
decreases secretion		 ISO [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein]
orlistat results in decreased secretion of CCK protein		 CTD PMID:11408251 PMID:18303078 PMID:18647814 NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084 		JBrowse link
G Ccna2 cyclin A2 decreases expression ISO Orlistat results in decreased expression of CCNA2 protein CTD PMID:30667213 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577 		JBrowse link
G Ccnd1 cyclin D1 increases expression
multiple interactions		 ISO Orlistat results in increased expression of CCND1 protein
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]		 CTD PMID:30667213 PMID:32045588 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccne1 cyclin E1 increases expression ISO Orlistat results in increased expression of CCNE1 protein CTD PMID:30667213 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Cd34 CD34 molecule multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein] CTD PMID:32045588 NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO Orlistat results in decreased expression of CDK1 protein CTD PMID:30667213 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO Orlistat results in decreased expression of CDK2 protein CTD PMID:30667213 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO Orlistat results in decreased expression of CDK4 protein CTD PMID:30667213 NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO Orlistat results in increased expression of CDKN1A protein CTD PMID:30667213 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression ISO orlistat results in increased expression of CDKN1B protein CTD PMID:15138278 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] CTD PMID:33476690 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412 		JBrowse link
G Cel carboxyl ester lipase decreases activity ISO orlistat results in decreased activity of CEL protein CTD PMID:11592731 PMID:12381337 NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035 		JBrowse link
G Clps colipase multiple interactions ISO orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] CTD PMID:15158758 NCBI chr20:6,620,529...6,622,709
Ensembl chr20:6,620,529...6,622,689 		JBrowse link
G Cpb2 carboxypeptidase B2 decreases expression ISO orlistat results in decreased expression of CPB2 protein CTD PMID:16959692 NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression ISO Orlistat results in decreased expression of CPT1A protein CTD PMID:30667213 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 decreases expression ISO Orlistat results in decreased expression of CPT2 protein CTD PMID:30667213 NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression ISO Orlistat results in increased expression of CYP3A4 mRNA; Orlistat results in increased expression of CYP3A4 protein CTD PMID:20599501 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Dagla diacylglycerol lipase, alpha decreases activity ISO orlistat results in decreased activity of DAGLA protein CTD PMID:16466961 NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO orlistat results in increased expression of DDIT3 mRNA CTD PMID:17283163 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 increases expression ISO orlistat results in increased expression of DDIT4 mRNA CTD PMID:18796435 NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105 		JBrowse link
G Eif2a eukaryotic translation initiation factor 2A increases phosphorylation
multiple interactions		 ISO orlistat results in increased phosphorylation of EIF2A protein
orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein
Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein]
orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]		 CTD PMID:17283163 PMID:20577697 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases response to substance
multiple interactions		 ISO EIF2AK3 gene mutant form results in increased susceptibility to orlistat
orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]		 CTD PMID:17283163 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif4e eukaryotic translation initiation factor 4E increases phosphorylation ISO orlistat results in increased phosphorylation of EIF4E protein CTD PMID:18796435 NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 affects response to substance
decreases expression
affects localization		 ISO ERBB2 protein affects the susceptibility to orlistat
orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein
orlistat affects the localization of ERBB2 protein		 CTD PMID:15870086 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA] CTD PMID:17283163 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Etv4 ETS variant transcription factor 4 increases expression ISO orlistat results in increased expression of ETV4 protein CTD PMID:15870086 NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974 		JBrowse link
G Fabp1 fatty acid binding protein 1 decreases expression ISO Orlistat results in decreased expression of FABP1 protein CTD PMID:30667213 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788 		JBrowse link
G Fas Fas cell surface death receptor decreases expression ISO Orlistat results in decreased expression of FAS mRNA CTD PMID:32347045 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Fasn fatty acid synthase affects binding
affects response to substance
multiple interactions
decreases activity
decreases expression		 ISO orlistat analog binds to FASN protein
FASN protein affects the susceptibility to orlistat
[Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [Orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; Orlistat binds to and results in decreased activity of FASN protein; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone]
orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein
[orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid]
Orlistat results in decreased expression of FASN protein		 CTD PMID:15026345 PMID:15138278 PMID:15870086 PMID:17012255 PMID:17618296 More... NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Gcg glucagon multiple interactions
decreases expression
decreases secretion		 ISO orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein]
orlistat results in decreased expression of GCG protein
orlistat results in decreased secretion of GCG protein		 CTD PMID:12915676 PMID:18647814 PMID:19837920 NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929 		JBrowse link
G Ghrl ghrelin and obestatin prepropeptide multiple interactions ISO orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein] CTD PMID:15998659 PMID:17138722 NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621 		JBrowse link
G Gip gastric inhibitory polypeptide decreases expression ISO orlistat results in decreased expression of GIP protein CTD PMID:12915676 NCBI chr10:80,968,360...80,976,506
Ensembl chr10:80,968,352...80,976,503 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein] CTD PMID:29479035 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GPX1 mRNA] CTD PMID:32450208 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024 		JBrowse link
G Gpx8 glutathione peroxidase 8 increases expression ISO orlistat results in increased expression of GPX8 mRNA CTD PMID:18796435 NCBI chr 2:44,676,448...44,680,042
Ensembl chr 2:44,676,454...44,680,195 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GSR protein] CTD PMID:32450208 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 decreases expression ISO orlistat results in decreased expression of HBA1 protein modified form CTD PMID:19207292 PMID:19461584 NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP orlistat inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein] CTD PMID:25087745 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO orlistat results in increased expression of HSPA5 mRNA CTD PMID:17283163 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Il10 interleukin 10 increases expression EXP Orlistat results in increased expression of IL10 mRNA CTD PMID:32450208 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA] CTD PMID:32450208 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] CTD PMID:21088047 PMID:32045588 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in increased expression of INS1 protein] CTD PMID:25087745 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Ins2 insulin 2 decreases expression
increases expression
affects expression
multiple interactions		 ISO orlistat results in decreased expression of INS protein
orlistat results in increased expression of INS protein
orlistat affects the expression of INS protein
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]		 CTD PMID:10095983 PMID:11274935 PMID:12915676 PMID:33476690 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G Kdelr3 KDEL endoplasmic reticulum protein retention receptor 3 increases expression ISO orlistat results in increased expression of KDELR3 mRNA CTD PMID:18796435 NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600 		JBrowse link
G Kdr kinase insert domain receptor decreases expression ISO orlistat results in decreased expression of KDR protein CTD PMID:17012255 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Krt81 keratin 81 increases expression ISO orlistat results in increased expression of KRT81 mRNA CTD PMID:18796435 NCBI chr 7:132,577,112...132,582,238
Ensembl chr 7:132,576,492...132,582,170 		JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP orlistat inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein] CTD PMID:25087745 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231 		JBrowse link
G Lep leptin multiple interactions ISO
EXP		 orlistat inhibits the reaction [Dietary Fats results in increased expression of LEP protein] CTD PMID:21332399 PMID:25087745 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262 		JBrowse link
G Lipf lipase F, gastric type decreases activity ISO orlistat results in decreased activity of LIPF protein CTD PMID:11408251 PMID:12381337 NCBI chr 1:231,493,498...231,511,845
Ensembl chr 1:231,493,498...231,511,845 		JBrowse link
G Lpl lipoprotein lipase decreases activity
multiple interactions		 ISO
EXP		 orlistat results in decreased activity of LPL protein
orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein]
orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein]
[orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides		 CTD PMID:12388125 PMID:12573449 PMID:15910848 PMID:15994321 PMID:18698144 More... NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein] CTD PMID:32045588 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein] CTD PMID:32045588 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] CTD PMID:32045588 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Napepld N-acyl phosphatidylethanolamine phospholipase D decreases activity EXP orlistat results in decreased activity of NAPEPLD protein CTD PMID:16466961 NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP
ISO		 Orlistat inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 mRNA]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA		 CTD PMID:32450208 PMID:33476690 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein] CTD PMID:32450208 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Npy neuropeptide Y increases expression ISO orlistat results in increased expression of NPY protein CTD PMID:15962606 NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases activity ISO orlistat results in increased activity of NR1I2 protein CTD PMID:20599501 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO Orlistat binds to and results in increased activity of NR1I3 protein alternative form CTD PMID:31312845 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Nts neurotensin multiple interactions ISO Orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; Orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein] CTD PMID:18303078 NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO [orlistat co-treated with Thapsigargin] results in increased cleavage of PARP1 protein
orlistat results in increased cleavage of PARP1 protein		 CTD PMID:15870086 PMID:17283163 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein] CTD PMID:32045588 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Pla2g7 phospholipase A2 group VII decreases activity
multiple interactions		 ISO orlistat results in decreased activity of PLA2G7 protein
[orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein		 CTD PMID:16911813 PMID:18513463 PMID:18657971 NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476 		JBrowse link
G Pnlip pancreatic lipase decreases secretion
decreases activity
multiple interactions
affects folding		 ISO
EXP		 orlistat results in decreased secretion of PNLIP protein
orlistat results in decreased activity of PNLIP protein
orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein]
orlistat affects the folding of PNLIP protein
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil]		 CTD PMID:11408251 PMID:11668201 PMID:12381337 PMID:15158758 PMID:19346257 NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654 		JBrowse link
G Pnliprp2 pancreatic lipase related protein 2 decreases activity ISO
EXP		 orlistat results in decreased activity of PNLIPRP2 protein
Orlistat results in decreased activity of PNLIPRP2 protein		 CTD PMID:9822688 PMID:17401110 NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434 		JBrowse link
G Pon1 paraoxonase 1 increases activity ISO orlistat results in increased activity of PON1 protein CTD PMID:11820148 PMID:17134960 NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360 		JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA] CTD PMID:33476690 NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression ISO Orlistat results in increased expression of PPARG mRNA CTD PMID:32347045 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Ppt1 palmitoyl-protein thioesterase 1 decreases expression ISO Orlistat results in decreased expression of PPT1 protein CTD PMID:30667213 NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048 		JBrowse link
G Ppy pancreatic polypeptide multiple interactions ISO orlistat inhibits the reaction [Triglycerides results in increased secretion of PPY protein] CTD PMID:15998659 NCBI chr10:87,054,747...87,056,044
Ensembl chr10:87,054,756...87,055,455 		JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions EXP
ISO		 orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein]
orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein]		 CTD PMID:18390901 PMID:19167487 NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978 		JBrowse link
G Pten phosphatase and tensin homolog increases expression
multiple interactions		 ISO Orlistat results in increased expression of PTEN protein
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]		 CTD PMID:32045588 NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein] CTD PMID:32045588 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Pyy peptide YY decreases secretion
multiple interactions		 ISO orlistat results in decreased secretion of PYY protein
orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein]		 CTD PMID:15998659 PMID:17138722 PMID:18647814 NCBI chr10:87,061,155...87,062,278
Ensembl chr10:87,061,161...87,061,815 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases phosphorylation ISO orlistat results in decreased phosphorylation of RB1 protein CTD PMID:15138278 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in increased expression of RELA mRNA] CTD PMID:32450208 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] CTD PMID:32045588 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
G Sec24d SEC24 homolog D, COPII coat complex component increases expression ISO orlistat results in increased expression of SEC24D mRNA CTD PMID:18796435 NCBI chr 2:211,418,557...211,526,588
Ensembl chr 2:211,418,623...211,526,587 		JBrowse link
G Skp2 S-phase kinase associated protein 2 multiple interactions
decreases expression		 ISO [orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein
orlistat results in decreased expression of SKP2 protein		 CTD PMID:15138278 NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO orlistat inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions
decreases expression		 ISO Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]
Orlistat results in decreased expression of SREBF1 protein		 CTD PMID:32045588 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Tf transferrin multiple interactions ISO [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] CTD PMID:33476690 NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA CTD PMID:33476690 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP		 Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]
Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA]		 CTD PMID:15994321 PMID:32045588 PMID:32450208 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfsf10 TNF superfamily member 10 increases response to substance ISO orlistat results in increased susceptibility to TNFSF10 protein CTD PMID:18796435 PMID:21406729 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tp53 tumor protein p53 multiple interactions EXP Orlistat inhibits the reaction [Dietary Fats results in increased expression of TP53 mRNA] CTD PMID:32450208 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions ISO Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] CTD PMID:33476690 NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA] CTD PMID:17283163 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19811
    chemical entity 19840
      atom 19809
        nonmetal atom 19747
          nitrogen atom 18962
            nitrogen molecular entity 18934
              organonitrogen compound 18783
                amino acid derivative 12476
                  leucine derivative 116
                    (1-Methylsulfonylpiperidin-4-yl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate 0
                    (2S)-2-[(2R,3S,4aS,7R,8R,8aS)-2,3,4'-trihydroxy-4,4,7,8a-tetramethyl-6'-oxospiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3,8-dihydrouro[2,3-e]isoindole]-7'-yl]-4-methylpentanoic acid 0
                    (2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid 0
                    (2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid methyl ester 0
                    (2S)-4-methyl-2-[[[5-(methylcarbamoyl)-1H-imidazol-4-yl]-oxomethyl]amino]pentanoic acid tert-butyl ester 0
                    (2S)-4-methyl-2-[[[5-[[5-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentylamino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]pentanoic acid tert-butyl ester 0
                    (2S)-4-methyl-2-[[oxo-(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]amino]pentanoic acid methyl ester 0
                    (2S)-4-methyl-2-[[oxo-[5-[oxo-[(phenylmethyl)amino]methyl]-1H-imidazol-4-yl]methyl]amino]pentanoic acid (phenylmethyl) ester 0
                    (2S)-4-methyl-2-[[oxo-[5-[oxo-[(phenylmethyl)amino]methyl]-1H-imidazol-4-yl]methyl]amino]pentanoic acid tert-butyl ester 0
                    (4-Benzyl-1-methylsulfonylpiperidin-4-yl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate 0
                    2-[(2-Hydroxy-3-methylbutanoyl)amino]-4-methylpentanoic acid 0
                    2-[(3S,4aR,7S,8S,8aR)-3,4'-dihydroxy-4,4,7,8a-tetramethyl-6'-oxospiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3,8-dihydrouro[2,3-e]isoindole]-7'-yl]-4-methylpentanoic acid 0
                    2-[(7-hydroxy-4-methyl-2-oxo-1-benzopyran-8-yl)methylamino]-4-methylpentanoic acid 0
                    2-[[2-[(5-cyano-4-oxo-6-phenyl-1H-pyrimidin-2-yl)thio]-1-oxoethyl]amino]-4-methylpentanoic acid methyl ester 0
                    2-[[9H-fluoren-9-ylmethoxy(oxo)methyl]amino]-4-methylpentanoic acid 0
                    4-Hydroxyprolylleucine 0
                    4-azaleucine 0
                    4-hydroxyleucine + 0
                    4-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoic acid (4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl) ester 0
                    5,5,5-trifluoroleucine 0
                    AM-4299-A 0
                    AM4299B 0
                    Abenquine B1 0
                    Actinoramide D 0
                    Actinoramide E 0
                    Actinoramide F 0
                    Aeruginosin 205 A 0
                    Aeruginosin 205 B 0
                    Aeruginosin 602 0
                    Aeruginosin 670 0
                    Aeruginosin 736 0
                    Aeruginosin 752 0
                    Aeruginosin 766 0
                    Aeruginosin 822 0
                    Aeruginosin 836 0
                    Aeruginosin 848 0
                    Aeruginosin 850 0
                    Aeruginosin 878A 0
                    Aeruginosin 878B 0
                    Aeruginosin 892 0
                    Aeruginosin BH462B 0
                    Aeruginosin DA495B 0
                    Aeruginosin K139 0
                    Aeruginosin LH650A 0
                    Aeruginosin LH650B 0
                    Azacoccone F 0
                    Biseokeaniamide C 0
                    Circinamide 0
                    D-leucine derivative + 0
                    Dentigerumycin C 0
                    Dentigerumycin D 0
                    Dysideaproline E 0
                    E-64c 0
                    Epanorin 0
                    Ethyl 4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate 0
                    FR-900137 0
                    Fendlerinine E 0
                    Fmoc-D-Leu-OH 0
                    Gaburedin B 0
                    Hypothallin 0
                    Incarnatapeptin A 0
                    L-Leucine, N-methyl-N-(2-methoxyethoxycarbonyl)-, heptadecyl ester 0
                    L-leucine derivative + 116
                    LSM-31374 0
                    Lipstatin 3
                    Mirabimide B 0
                    N-(1-Deoxy-1-fructosyl)leucine 0
                    N-(indole-3-acetyl)leucine + 0
                    N-Benzoyl-l-leucine methyl ester 0
                    N-Palmitoyl leucine 0
                    N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamic acid (phenylmethyl) ester 0
                    N-acetyl-leucine 0
                    N-lactoyl-Leucine 0
                    N-methylleucine 0
                    Norepanorin 0
                    Penazaphilone A 0
                    Penazaphilone B 0
                    Penicillatide A 0
                    Phenyl-Leucine 0
                    SMTP-5 0
                    SMTP-5D 0
                    Sodium 0
                    Sodium 0
                    Sodium 0
                    Sodium 0
                    Sodium 0
                    Sodium 0
                    Spumigin 574 0
                    Stachartin D 0
                    Sterenin M 0
                    Tert-butyl 4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate 0
                    Tert-butyl 4-benzyl-4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate 0
                    Tert-butyl 4-ethyl-4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate 0
                    Tert-butyl n-[1-(aminocarbonyl)-3-methylbutyl]carbamate 0
                    WF-14865B 0
                    gamma-L-glutamyl-L-leucine 0
                    l-Leucine, trimethylsilyl ester 0
                    peptidyl-leucine 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19811
    subatomic particle 19809
      composite particle 19809
        hadron 19840
          baryon 19809
            nucleon 19809
              atomic nucleus 19809
                atom 19809
                  main group element atom 19759
                    main group molecular entity 19759
                      p-block molecular entity 19759
                        carbon group molecular entity 19708
                          organic molecular entity 19705
                            heteroorganic entity 19459
                              organonitrogen compound 18783
                                amino acid derivative 12476
                                  leucine derivative 116
                                    (1-Methylsulfonylpiperidin-4-yl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate 0
                                    (2S)-2-[(2R,3S,4aS,7R,8R,8aS)-2,3,4'-trihydroxy-4,4,7,8a-tetramethyl-6'-oxospiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3,8-dihydrouro[2,3-e]isoindole]-7'-yl]-4-methylpentanoic acid 0
                                    (2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid 0
                                    (2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid methyl ester 0
                                    (2S)-4-methyl-2-[[[5-(methylcarbamoyl)-1H-imidazol-4-yl]-oxomethyl]amino]pentanoic acid tert-butyl ester 0
                                    (2S)-4-methyl-2-[[[5-[[5-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentylamino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]pentanoic acid tert-butyl ester 0
                                    (2S)-4-methyl-2-[[oxo-(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]amino]pentanoic acid methyl ester 0
                                    (2S)-4-methyl-2-[[oxo-[5-[oxo-[(phenylmethyl)amino]methyl]-1H-imidazol-4-yl]methyl]amino]pentanoic acid (phenylmethyl) ester 0
                                    (2S)-4-methyl-2-[[oxo-[5-[oxo-[(phenylmethyl)amino]methyl]-1H-imidazol-4-yl]methyl]amino]pentanoic acid tert-butyl ester 0
                                    (4-Benzyl-1-methylsulfonylpiperidin-4-yl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate 0
                                    2-[(2-Hydroxy-3-methylbutanoyl)amino]-4-methylpentanoic acid 0
                                    2-[(3S,4aR,7S,8S,8aR)-3,4'-dihydroxy-4,4,7,8a-tetramethyl-6'-oxospiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3,8-dihydrouro[2,3-e]isoindole]-7'-yl]-4-methylpentanoic acid 0
                                    2-[(7-hydroxy-4-methyl-2-oxo-1-benzopyran-8-yl)methylamino]-4-methylpentanoic acid 0
                                    2-[[2-[(5-cyano-4-oxo-6-phenyl-1H-pyrimidin-2-yl)thio]-1-oxoethyl]amino]-4-methylpentanoic acid methyl ester 0
                                    2-[[9H-fluoren-9-ylmethoxy(oxo)methyl]amino]-4-methylpentanoic acid 0
                                    4-Hydroxyprolylleucine 0
                                    4-azaleucine 0
                                    4-hydroxyleucine + 0
                                    4-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoic acid (4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl) ester 0
                                    5,5,5-trifluoroleucine 0
                                    AM-4299-A 0
                                    AM4299B 0
                                    Abenquine B1 0
                                    Actinoramide D 0
                                    Actinoramide E 0
                                    Actinoramide F 0
                                    Aeruginosin 205 A 0
                                    Aeruginosin 205 B 0
                                    Aeruginosin 602 0
                                    Aeruginosin 670 0
                                    Aeruginosin 736 0
                                    Aeruginosin 752 0
                                    Aeruginosin 766 0
                                    Aeruginosin 822 0
                                    Aeruginosin 836 0
                                    Aeruginosin 848 0
                                    Aeruginosin 850 0
                                    Aeruginosin 878A 0
                                    Aeruginosin 878B 0
                                    Aeruginosin 892 0
                                    Aeruginosin BH462B 0
                                    Aeruginosin DA495B 0
                                    Aeruginosin K139 0
                                    Aeruginosin LH650A 0
                                    Aeruginosin LH650B 0
                                    Azacoccone F 0
                                    Biseokeaniamide C 0
                                    Circinamide 0
                                    D-leucine derivative + 0
                                    Dentigerumycin C 0
                                    Dentigerumycin D 0
                                    Dysideaproline E 0
                                    E-64c 0
                                    Epanorin 0
                                    Ethyl 4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate 0
                                    FR-900137 0
                                    Fendlerinine E 0
                                    Fmoc-D-Leu-OH 0
                                    Gaburedin B 0
                                    Hypothallin 0
                                    Incarnatapeptin A 0
                                    L-Leucine, N-methyl-N-(2-methoxyethoxycarbonyl)-, heptadecyl ester 0
                                    L-leucine derivative + 116
                                    LSM-31374 0
                                    Lipstatin 3
                                    Mirabimide B 0
                                    N-(1-Deoxy-1-fructosyl)leucine 0
                                    N-(indole-3-acetyl)leucine + 0
                                    N-Benzoyl-l-leucine methyl ester 0
                                    N-Palmitoyl leucine 0
                                    N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamic acid (phenylmethyl) ester 0
                                    N-acetyl-leucine 0
                                    N-lactoyl-Leucine 0
                                    N-methylleucine 0
                                    Norepanorin 0
                                    Penazaphilone A 0
                                    Penazaphilone B 0
                                    Penicillatide A 0
                                    Phenyl-Leucine 0
                                    SMTP-5 0
                                    SMTP-5D 0
                                    Sodium 0
                                    Sodium 0
                                    Sodium 0
                                    Sodium 0
                                    Sodium 0
                                    Sodium 0
                                    Spumigin 574 0
                                    Stachartin D 0
                                    Sterenin M 0
                                    Tert-butyl 4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate 0
                                    Tert-butyl 4-benzyl-4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate 0
                                    Tert-butyl 4-ethyl-4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate 0
                                    Tert-butyl n-[1-(aminocarbonyl)-3-methylbutyl]carbamate 0
                                    WF-14865B 0
                                    gamma-L-glutamyl-L-leucine 0
                                    l-Leucine, trimethylsilyl ester 0
                                    peptidyl-leucine 0
paths to the root